

AGIOS PHARMACEUTICALS INC  
Form SC 13D/A  
January 23, 2018

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**SCHEDULE 13D**

**Under the Securities Exchange Act of 1934**

**(Amendment No. 4)\***

**Agios Pharmaceuticals, Inc.**

**(Name of Issuer)**

**Common Stock, \$0.0001 par value**

**(Title of Class of Securities)**

**00847X104**

**(CUSIP Number)**

**Mark J. Alles**

**Chief Executive Officer**

**Celgene Corporation**

**86 Morris Avenue**

**Summit, New Jersey 07901**

**(908) 673-9000**

**(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)**

**January 23, 2018**

**(Date of Event Which Requires Filing of This Statement)**

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g) check the following box: "

**Note:** Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to \*the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



SCHEDULE 13D

CUSIP No. 00847X104

Name of reporting person:

1

CELGENE SWITZERLAND LLC

Check the appropriate box if a member of a group\*

2

(a)  (b)   
SEC use only

3

Source of funds\*

4

WC

Check box if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5

Citizenship or place of organization

6

Delaware, U.S.A.

Number of Sole voting power

shares 7

beneficially -0-  
Shared voting power

owned by 8

each 624,575

reporting 9 Sole dispositive power

person

with -0-  
10 Shared dispositive power

624,575  
Aggregate amount beneficially owned by each reporting person

11

624,575  
Check box if the aggregate amount in Row (11) excludes certain shares\* ..

12

Percent of class represented by amount in Row (11)

13

1.1%<sup>(1)</sup>  
Type of reporting person\*

14

OO

The percentage ownership is based upon 55,707,542 shares of Common Stock outstanding as of January 23, 2018, which includes (a) 48,617,989 shares of Common Stock outstanding as of September 30, 2017, as reported by (1) Agios in its prospectus filed with the Securities and Exchange Commission on January 18, 2018, and (b) 7,089,553 shares of Common Stock issued by Agios in the Offering.

SCHEDULE 13D

CUSIP No. 00847X104

Name of reporting person:

1 I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITY ONLY)

CELGENE EUROPEAN INVESTMENT COMPANY LLC

90-0587060

Check the appropriate box if a member of a group\*

2

(a)  (b)   
SEC use only

3

Source of funds\*

4

WC

Check box if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5

Citizenship or place of organization

6

Delaware, U.S.A.

Number of Sole voting power

shares 7

beneficially -0-

8 Shared voting power

owned by

each

Edgar Filing: AGIOS PHARMACEUTICALS INC - Form SC 13D/A

reporting	4,010,926
person	Sole dispositive power
with	9
	-0-
	10 Shared dispositive power

4,010,926

Aggregate amount beneficially owned by each reporting person

11

4,010,926

Check box if the aggregate amount in Row (11) excludes certain shares\*

12

Percent of class represented by amount in Row (11)

13

7.2%<sup>(1)</sup>

Type of reporting person\*

14

OO (limited liability company)

The percentage ownership is based upon 55,707,542 shares of Common Stock outstanding as of January 23, 2018, which includes (a) 48,617,989 shares of Common Stock outstanding as of September 30, 2017, as reported by (1) Agios in its prospectus filed with the Securities and Exchange Commission on January 18, 2018, and (b) 7,089,553 shares of Common Stock issued by Agios in the Offering.

SCHEDULE 13D

CUSIP No. 00847X104

Name of reporting person:

1 I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITY ONLY)

CELGENE ALPINE INVESTMENT CO., LLC

45-4054818

Check the appropriate box if a member of a group\*

2

(a)  (b)   
SEC use only

3

Source of funds\*

4

WC

Check box if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5

Citizenship or place of organization

6

Delaware, U.S.A.

Number of Sole voting power

shares 7

beneficially -0-

8 Shared voting power

owned by

each

reporting	708,333
person	Sole dispositive power
with	9
	-0-
	10 Shared dispositive power

708,333

Aggregate amount beneficially owned by each reporting person

11

708,333

Check box if the aggregate amount in Row (11) excludes certain shares\*

12

Percent of class represented by amount in Row (11)

13

1.3%<sup>(1)</sup>

Type of reporting person\*

14

OO (limited liability company)

The percentage ownership is based upon 55,707,542 shares of Common Stock outstanding as of January 23, 2018, which includes (a) 48,617,989 shares of Common Stock outstanding as of September 30, 2017, as reported by (1) Agios in its prospectus filed with the Securities and Exchange Commission on January 18, 2018, and (b) 7,089,553 shares of Common Stock issued by Agios in the Offering.

SCHEDULE 13D

CUSIP No. 00847X104

Name of reporting person:

1 I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITY ONLY)

CELGENE CORPORATION

22-2711928

Check the appropriate box if a member of a group\*

2

(a)  (b)   
SEC use only

3

Source of funds\*

4

WC

Check box if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5

Citizenship or place of organization

6

Delaware, U.S.A.

Number of Sole voting power

shares 7

beneficially 1,374,599

owned by 8 Shared voting power

owned by

each

reporting	5,343,834
person	Sole dispositive power
with	9
	1,374,599
	10 Shared dispositive power

5,343,834  
Aggregate amount beneficially owned by each reporting person

11

6,718,433  
Check box if the aggregate amount in Row (11) excludes certain shares\*

12

Percent of class represented by amount in Row (11)

13

12.1%<sup>(1)</sup>  
Type of reporting person\*

14

CO

The percentage ownership is based upon 55,707,542 shares of Common Stock outstanding as of January 23, 2018, which includes (a) 48,617,989 shares of Common Stock outstanding as of September 30, 2017, as reported by (1) Agios in its prospectus filed with the Securities and Exchange Commission on January 18, 2018, and (b) 7,089,553 shares of Common Stock issued by Agios in the Offering.

This Amendment No. 4 amends the Schedule 13D (the “**Schedule 13D**”) filed with the Securities and Exchange Commission (the “**Commission**”) on August 6, 2013 by Celgene European Investment Company LLC, Celgene Alpine Investment Co., LLC (“**Celgene Alpine**”) and Celgene Corporation (“**Celgene**”), as amended by Amendment No. 1 thereto filed with the Commission on April 30, 2014, as amended by Amendment No. 2 thereto filed with the Commission on December 17, 2014, and as amended by Amendment No. 3 thereto filed with the Commission on April 24, 2017, with respect to common stock, par value \$0.0001 per share (“**Common Stock**”), of Agios Pharmaceuticals, Inc., a Delaware corporation (“**Agios**”). Capitalized terms used, but not defined herein, have the meanings ascribed to them in the Schedule 13D.

**Item 1. Security and Issuer.**

No modification.

**Item 2. Identity and Background.**

Item 2 is hereby amended and supplemented by adding the Schedule A hereto. During the past five years, none of the Reporting Persons, nor, to the knowledge of the Reporting Persons, any of the persons listed on Schedule A hereto, has been (i) convicted in a criminal proceeding (excluding traffic violations and similar misdemeanors), or (ii) a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

**Item 3. Source and Amount of Funds or Other Consideration.**

No modification.

**Item 4. Purpose of Transaction.**

Item 4 is hereby amended and supplemented by adding the following:

On January 23, 2018, Agios completed its underwritten public offering (the “**Offering**”) of 7,089,553 shares of Common Stock at a public offering price of \$67.00 per share, and Celgene purchased (the “**Purchase**”) 851,154 shares of Common Stock at a purchase price of \$67.00 per share in the Offering for investment purposes. Following the

Offering and the Purchase, Celgene beneficially owns 1,374,599 shares of Common Stock and Celgene shares beneficial ownership of an aggregate of 6,718,433 shares of Common Stock, collectively representing approximately 12.1% of the shares of Common Stock outstanding as of January 23, 2018, which includes (a) 48,617,989 shares of Common Stock outstanding as of September 30, 2017, as reported by Agios in its prospectus filed with the Commission on January 18, 2018, and (b) 7,089,553 shares of Common Stock issued by Agios in the Offering.

**Item 5. Interest in Securities of the Issuer.**

Item 5(a)-(c) is hereby amended and restated as follows:

On January 23, 2018, Agios completed the Offering and Celgene completed the Purchase. Following the Offering and the Purchase, Celgene beneficially owns 1,374,599 shares of Common Stock and Celgene shares beneficial ownership of an aggregate of 6,718,433 shares of Common Stock, collectively representing approximately 12.1% of the shares of Common Stock outstanding as of January 23, 2018, which includes (a) 48,617,989 shares of Common Stock outstanding as of September 30, 2017, as reported by Agios in its prospectus filed with the Commission on January 18, 2018, and (b) 7,089,553 shares of Common Stock issued by Agios in the Offering.

**Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.**

Item 6 is hereby amended and supplemented by adding the following:

In connection with the Offering, Celgene and the underwriters of the Offering entered into a letter agreement (the “**Lock-up Agreement**”), pursuant to which Celgene agreed not to, among other things, offer, pledge, sell or transfer any Agios securities for a period of 60 days after the date of the final prospectus relating to the Offering without the consent of the underwriters of the Offering, subject to certain limited exceptions.

A copy of the Form of Lock-up Agreement is filed as an exhibit to this Amendment and incorporated herein by reference.

**Item 7. Material to Be Filed as Exhibits.**

Item 7 is hereby amended and supplemented by adding the following:

Exhibit 7 – Form of Lock-up Agreement.



**SCHEDULE A****Name, business address, present principal occupation or employment and place of citizenship of the directors and executive officers of the Reporting Persons**

The name, business address and present principal occupation or employment of each of the directors and executive officers of the Reporting Persons are set forth below. The business address of each director and executive officer is c/o 86 Morris Avenue, Summit, New Jersey 07901. Unless otherwise indicated, each director and executive officer is a citizen of the United States.

**CELGENE CORPORATION — BOARD OF DIRECTORS**

<b>Name and Position</b>	<b>Present Principal Occupation or Employment</b>
<b>Robert J. Hugin</b> Executive Chairman	Executive Chairman of Celgene Corporation
<b>Mark J. Alles</b> Chief Executive Officer	Chief Executive Officer of Celgene Corporation
<b>Richard W. Barker, D.Phil.</b> Director (Citizen of the United Kingdom)	Director of the Centre for Accelerating Medical Innovations; Chairman of the Health Innovation Network of South London, UK; Chairman of International Health Partners; Chairman of Image Analysis Group
<b>Michael W. Bonney</b> Director	Formerly Chief Executive Officer and a director of Cubist Pharmaceuticals Inc.; Chairman of the Board of Alnylam Pharmaceuticals, Inc.; member of the Board of Directors of Global Blood Therapeutics, Inc.; Trustee of the Tekla complex of life sciences and dedicated funds; Board of Trustee Chair of Bates College
<b>Michael D. Casey</b> Director	Formerly Chairman, President, Chief Executive Officer and a director of Matrix Pharmaceutical, Inc.; Director of Abaxis, Inc.
<b>Carrie S. Cox</b>	Chairman of the Board of Directors and Chief Executive Officer of Humacyte, Inc.; member of Board of Directors of Texas Instruments; member of Board of Directors of

Edgar Filing: AGIOS PHARMACEUTICALS INC - Form SC 13D/A

Director	Cardinal Health, Inc.
<b>Michael A. Friedman, M.D.</b>	Emeritus Chief Executive Officer of City of Hope; member of Board of Directors of MannKind Corporation; member of Board of Directors of Smith & Nephew plc; member of the Board of Directors of Intuitive Surgical, Inc.; member of Board of Trustees of Tulane University
Director	
<b>Julia A. Haller, M.D.</b>	Ophthalmologist-in-Chief of the Wills Eye Hospital, Philadelphia, PA; Professor and Chair of the Department of Ophthalmology at Jefferson Medical College of Thomas Jefferson University and Thomas Jefferson University Hospitals
Director	
<b>Gilla Kaplan, Ph.D.</b>	Director of the Global Health Program, Tuberculosis, at the Bill and Melinda Gates Foundation
Director	
<b>James J. Loughlin</b>	Formerly National Director of the Pharmaceuticals Practice at KPMG LLP; member of Board of Directors of each of Edge Therapeutics, Inc.
Director	
<b>Ernest Mario, Ph.D.</b>	Chairman of the Board of each of Soleno Therapeutics Inc. (formerly Capnia, Inc.) and Chimerix Inc.; member of the Board of Directors of Tonix Pharmaceutical Holding Corp.
Director	

**CELGENE CORPORATION — EXECUTIVE OFFICERS**

<b>Name</b>	<b>Title</b>
<b>Robert J. Hugin</b>	Executive Chairman
<b>Mark J. Alles</b>	Chief Executive Officer
<b>Peter N. Kellogg</b>	Executive Vice President and Chief Financial Officer
<b>Scott A. Smith</b>	President and Chief Operating Officer
<b>Terrie Curran</b>	President, Inflammation & Immunology
<b>Rupert Vessey</b>	President, Research and Early Development
<b>Nadim Ahmed</b>	President, Hematology & Oncology
<b>Gerald Masoudi</b>	Executive Vice President, General Counsel and Corporate Secretary

**CELGENE SWITZERLAND LLC**

<b>Name</b>	<b>Present Principal Occupation or Employment</b>
-------------	---

<b>Kevin Mello</b> (Citizen of Bermuda)	Manager of Celgene Switzerland LLC
--	------------------------------------

**CELGENE EUROPEAN INVESTMENT COMPANY LLC**

<b>Name</b>	<b>Present Principal Occupation or Employment</b>
-------------	---

<b>Kevin Mello</b> (Citizen of Bermuda)	Manager of Celgene European Investment Company LLC
--	--

**CELGENE ALPINE INVESTMENT CO., LLC**

<b>Name</b>	<b>Present Principal Occupation or Employment</b>
<b>Kevin Mello</b> (Citizen of Bermuda)	Manager of Celgene Alpine Investment Co., LLC